Summarized by Masters of Longevity from Longevity Technology.
Profile of a preclinical plasmid gene therapy company that reached the XPRIZE Healthspan final ten and plans a large placebo-controlled human trial testing multi-gene interventions for aging-related decline.
Key Takeaways
- Minicircle was named one of ten XPRIZE Healthspan Milestone 2 finalists and received $1 million in funding.
- The company develops non-viral minicircle DNA vectors delivering genes without genomic integration and targets reversible subcutaneous administration.
- Lead candidate Follistatin (FST-344) aims to enhance muscle mass and metabolic health while a Klotho program is planned for 2026.
